$3.59 Earnings Per Share Expected for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) This Quarter

Analysts forecast that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) will post earnings per share (EPS) of $3.59 for the current quarter, Zacks reports. Eight analysts have made estimates for Vertex Pharmaceuticals’ earnings. The lowest EPS estimate is $3.32 and the highest is $3.83. Vertex Pharmaceuticals posted earnings per share of $2.98 during the same quarter last year, which would indicate a positive year over year growth rate of 20.5%. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Vertex Pharmaceuticals will report full-year earnings of $14.58 per share for the current financial year, with EPS estimates ranging from $14.12 to $15.23. For the next financial year, analysts forecast that the business will report earnings of $15.34 per share, with EPS estimates ranging from $14.14 to $17.51. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Vertex Pharmaceuticals.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Rating) last posted its earnings results on Wednesday, January 26th. The pharmaceutical company reported $3.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.91 by $0.27. Vertex Pharmaceuticals had a net margin of 30.92% and a return on equity of 32.33%. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $1.99 billion. During the same period last year, the business posted $2.22 earnings per share.

VRTX has been the subject of a number of analyst reports. Royal Bank of Canada downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $269.00 price objective for the company. in a research report on Thursday, February 3rd. Morgan Stanley lifted their price objective on shares of Vertex Pharmaceuticals from $203.00 to $208.00 and gave the company an “underweight” rating in a research report on Thursday, January 27th. Wolfe Research lifted their price objective on shares of Vertex Pharmaceuticals from $271.00 to $282.00 and gave the company an “outperform” rating in a research report on Thursday, January 27th. TheStreet upgraded shares of Vertex Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Thursday, December 16th. Finally, Oppenheimer raised their target price on shares of Vertex Pharmaceuticals from $305.00 to $350.00 in a research note on Monday, April 4th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $269.95.

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 15,789 shares of the firm’s stock in a transaction dated Wednesday, April 13th. The shares were sold at an average price of $289.04, for a total value of $4,563,652.56. Following the transaction, the chairman now directly owns 74,160 shares of the company’s stock, valued at approximately $21,435,206.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ourania Tatsis sold 325 shares of the firm’s stock in a transaction dated Friday, February 25th. The shares were sold at an average price of $230.95, for a total transaction of $75,058.75. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,623 shares of company stock worth $13,527,514. Insiders own 0.70% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Pensionfund Sabic bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $2,525,000. Hudson Bay Capital Management LP grew its holdings in shares of Vertex Pharmaceuticals by 13.6% during the 3rd quarter. Hudson Bay Capital Management LP now owns 62,500 shares of the pharmaceutical company’s stock valued at $11,337,000 after purchasing an additional 7,500 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in Vertex Pharmaceuticals by 3.9% during the 3rd quarter. Janney Montgomery Scott LLC now owns 52,448 shares of the pharmaceutical company’s stock worth $9,514,000 after acquiring an additional 1,945 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG grew its holdings in Vertex Pharmaceuticals by 5.4% during the 3rd quarter. B. Metzler seel. Sohn & Co. Holding AG now owns 19,463 shares of the pharmaceutical company’s stock worth $3,530,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Meiji Yasuda Life Insurance Co grew its holdings in Vertex Pharmaceuticals by 16.1% during the 3rd quarter. Meiji Yasuda Life Insurance Co now owns 7,422 shares of the pharmaceutical company’s stock worth $1,346,000 after acquiring an additional 1,030 shares during the last quarter. 90.30% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals stock opened at $287.97 on Tuesday. The company has a market cap of $73.59 billion, a P/E ratio of 31.89, a price-to-earnings-growth ratio of 1.42 and a beta of 0.62. Vertex Pharmaceuticals has a 1-year low of $176.36 and a 1-year high of $292.75. The company has a fifty day simple moving average of $248.40 and a 200 day simple moving average of $219.45. The company has a current ratio of 4.46, a quick ratio of 4.30 and a debt-to-equity ratio of 0.05.

Vertex Pharmaceuticals Company Profile (Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Further Reading

Get a free copy of the Zacks research report on Vertex Pharmaceuticals (VRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.